Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC

Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/161597

Title:	Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
Authors:	Mok, T. Saijo, N. Thongprasert, S. Yang, J. C. -H. Wu, Y. -L. Young, H. Haddad, V. Jiang, H. Fukuoka, M.
Issue Date:	2015
Journal Issue:	26
Start page/Pages:	129-129
Source:	Ann. Oncol.
URI:	http://ntur.lib.ntu.edu.tw//handle/246246/280156
Appears in Collections:	腫瘤醫學研究所

Show full item record

checked on Sep 25, 2020

Check